FDA expects that establishing user fees for the OTC monograph program would yield benefits including spurring product innovation by drug firms and timely evaluations by the agency on the safety of ingredients proposed for a monograph.
The agency scheduled a public meeting for June 10 and has opened a docket for stakeholder input on the potential development of a user fee program for OTC monograph drugs,...